Medicina de Familia-SEMERGEN最新文献_第2页

Multiple eruptive xanthomas

IF 0.9

Medicina de Familia-SEMERGEN Pub Date : 2025-03-25 DOI: 10.1016/j.semerg.2025.102479

M. Mansilla-Polo , S. Becerril-Andrés , I. Torres-Navarro

引用次数: 0

El papel indispensable de la atención primaria rural: una llamada a la acción

IF 0.9

Medicina de Familia-SEMERGEN Pub Date : 2025-03-25 DOI: 10.1016/j.semerg.2025.102480

A. González Cabrera

引用次数: 0

Escorbuto: cómo sospechar una enfermedad olvidada

IF 0.9

Medicina de Familia-SEMERGEN Pub Date : 2025-03-25 DOI: 10.1016/j.semerg.2025.102474

C. Ferrín Castro , A. Martínez Baladrón , C. Fernández Domato

引用次数: 0

Estrategia de formación para una sociedad científica de médicos de familia: «Un enfoque integral hacia la excelencia»

IF 0.9

Medicina de Familia-SEMERGEN Pub Date : 2025-03-25 DOI: 10.1016/j.semerg.2025.102481

V. Pallarés-Carratalá , C. Cols-Sagarra , L. Martínez-Berganza Asensio , A. Segura-Grau , J. Ibañez , M. Matosas-Fonolleda , J. Cohen , R.M. Micó-Pérez , J. Polo-García , en nombre del grupo de trabajo de la Agencia de Formación de SEMERGEN

{"title":"Estrategia de formación para una sociedad científica de médicos de familia: «Un enfoque integral hacia la excelencia»","authors":"V. Pallarés-Carratalá , C. Cols-Sagarra , L. Martínez-Berganza Asensio , A. Segura-Grau , J. Ibañez , M. Matosas-Fonolleda , J. Cohen , R.M. Micó-Pérez , J. Polo-García , en nombre del grupo de trabajo de la Agencia de Formación de SEMERGEN","doi":"10.1016/j.semerg.2025.102481","DOIUrl":"10.1016/j.semerg.2025.102481","url":null,"abstract":"<div><h3>Introduction and objective</h3><div>This work analyzes the importance of a comprehensive training strategy from a scientific society of primary care physicians for continuing medical education. A strategy called “an integral approach towards excellence” is proposed, encompassing various key aspects.</div></div><div><h3>Methods</h3><div>The methodology employed includes a diagnostic phase, based on individual interviews and a survey, and a strategy design phase. The diagnosis focused on 6 dimensions: competencies, knowledge, methodology, satisfaction, evaluation, and organization.</div></div><div><h3>Results</h3><div>As a result, 8 strategic lines were articulated, ranging from positioning the society as a reference to the internationalization of training. The strategy emphasizes the importance of adapting training to the specific needs of physicians, promoting research and innovation, and addressing current challenges such as the incorporation of artificial intelligence in medical practice.</div></div><div><h3>Conclusion</h3><div>An effective training strategy from a scientific society should include competency-based continuing education programs and collaboration with academic and technological institutions, in order to respond to current and future challenges in medicine.</div></div>","PeriodicalId":53212,"journal":{"name":"Medicina de Familia-SEMERGEN","volume":"51 4","pages":"Article 102481"},"PeriodicalIF":0.9,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143696142","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Effects of sleep on sarcopenia in individuals with metabolic syndrome: A systematic review 睡眠对代谢综合征患者肌肉疏松症的影响：系统综述

IF 0.9

Medicina de Familia-SEMERGEN Pub Date : 2025-03-25 DOI: 10.1016/j.semerg.2025.102483

I. de Frutos-Galindo , D. Catalina-Palomares , P. Yubero-García , L. Botella-Juan , D. Vargas-Caraballo-Lockwood , A. Marcos-Delgado , T. Fernández-Villa

{"title":"Effects of sleep on sarcopenia in individuals with metabolic syndrome: A systematic review","authors":"I. de Frutos-Galindo , D. Catalina-Palomares , P. Yubero-García , L. Botella-Juan , D. Vargas-Caraballo-Lockwood , A. Marcos-Delgado , T. Fernández-Villa","doi":"10.1016/j.semerg.2025.102483","DOIUrl":"10.1016/j.semerg.2025.102483","url":null,"abstract":"<div><div>Sarcopenia and metabolic syndrome are present in a large percentage of the elderly population throughout the world. Much of its management is focused on primary prevention, and considering that sleep disturbances also accompany the same aging process associated with these two pathologies, we propose a relationship between sleep impairment and the development of sarcopenia in individuals with metabolic syndrome. A search was carried out in databases following he PRISMA scheme, obtaining fifteen studies. As for the main results: four of eight studies referring to sleep duration relate more than nine hours of sleep with an increased risk of sarcopenia, three of the five studies relate poorer sleep quality with worse body composition data or increased risk of sarcopenia and two studies related late chronotype with a higher risk of sarcopenia and metabolic syndrome. After analyzing the disparity of outcomes, it is necessary to homogenize methodologies to compare the different results.</div></div>","PeriodicalId":53212,"journal":{"name":"Medicina de Familia-SEMERGEN","volume":"51 4","pages":"Article 102483"},"PeriodicalIF":0.9,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143696143","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Nirmatrelvir/ritonavir prescription and the risk of hospitalization and death in COVID-19 outpatients

IF 0.9

Medicina de Familia-SEMERGEN Pub Date : 2025-03-25 DOI: 10.1016/j.semerg.2025.102461

H.R. Vargas-Sánchez , J.C. Tomás-López , E. Guzmán-Medina , A. Alarcón-López , E. Krug-Llamas , E. Arizmendi-Uribe , H. Domínguez-Zárate , J.E. Fernández-Gárate , I.J. Ascencio-Montiel

{"title":"Nirmatrelvir/ritonavir prescription and the risk of hospitalization and death in COVID-19 outpatients","authors":"H.R. Vargas-Sánchez , J.C. Tomás-López , E. Guzmán-Medina , A. Alarcón-López , E. Krug-Llamas , E. Arizmendi-Uribe , H. Domínguez-Zárate , J.E. Fernández-Gárate , I.J. Ascencio-Montiel","doi":"10.1016/j.semerg.2025.102461","DOIUrl":"10.1016/j.semerg.2025.102461","url":null,"abstract":"<div><h3>Objective</h3><div>The nirmatrelvir/ritonavir is an oral combination of antiviral drugs used to treat the COVID-19. In this study we evaluated the risk of hospitalization and death, comparing COVID-19 patients who received and did not receive ambulatory nirmatrelvir/ritonavir prescription.</div></div><div><h3>Material and methods</h3><div>A two-group comparative study was carried out using data from the Mexican Institute of Social Security medical information systems. We analyzed of 83,348 ambulatory patients aged 18 years old and over and with laboratory confirmed SARS-CoV-2 infection during the period from September 12th, 2022, to September 30th, 2023. Of them, 27,437 received nirmatrelvir/ritonavir prescription (32.9%) and 55,911 did not (67.1%). We compared the 60-day COVID-19 related hospitalization and all-cause death risk among groups using a multivariate Poisson regression model.</div></div><div><h3>Results</h3><div>The 60-day COVID-19 related hospitalization and all-cause death combined incidence was 0.13% in the patients who received nirmatrelvir/ritonavir and 0.26% among the cases who did not receive the prescription. In the multivariate model, after adjusting for age, sex, and previous medical conditions such as chronic kidney disease, chronic obstructive pulmonary disease and cardiovascular disease, the nirmatrelvir/ritonavir prescription was associated with a decrease in 60-day hospitalization and death, with an adjusted risk ratio of 0.52 (95% confidence interval from 0.36 to 0.75).</div></div><div><h3>Conclusions</h3><div>Our data supports that nirmatrelvir/ritonavir prescription is associated with a risk reduction of 60-day COVID-19 related hospitalization and death, in outpatients with COVID-19.</div></div>","PeriodicalId":53212,"journal":{"name":"Medicina de Familia-SEMERGEN","volume":"51 6","pages":"Article 102461"},"PeriodicalIF":0.9,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143696956","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Aproximación práctica del paciente con hipercolesterolemia en España. Documento de posicionamiento de SEMERGEN

IF 0.9

Medicina de Familia-SEMERGEN Pub Date : 2025-03-25 DOI: 10.1016/j.semerg.2025.102460

S. Cinza-Sanjurjo , V. Pallarés-Carratalá , A. Díaz Rodríguez , D. Fierro-González , M. Turégano-Yedro , J. Polo-García

{"title":"Aproximación práctica del paciente con hipercolesterolemia en España. Documento de posicionamiento de SEMERGEN","authors":"S. Cinza-Sanjurjo , V. Pallarés-Carratalá , A. Díaz Rodríguez , D. Fierro-González , M. Turégano-Yedro , J. Polo-García","doi":"10.1016/j.semerg.2025.102460","DOIUrl":"10.1016/j.semerg.2025.102460","url":null,"abstract":"<div><div>Hypercholesterolemia, specifically the increase in the set of lipoproteins containing apolipoproteinB and, in particular, low-density lipoprotein cholesterol (LDL-C), together with the decrease in high-density lipoprotein cholesterol (HDL-C) constitute the etiopathogenic basis of atherosclerotic vascular disease. Multiple clinical trials have shown that lowering LDL-C by lipid-lowering therapy is associated with a significant decrease in the risk of vascular complications. Thus, LDL-C is the main therapeutic target in patients with dyslipidemia. Unfortunately, current LDL-C control figures are still very low, partly due to insufficient intensification of lipid-lowering therapy, but also due to the need for new tools to achieve these goals. This paper reviews the different lipid-lowering treatment options, including the latest available therapies, and provides a practical approach to achieving LDL-C control goals in patients with hypercholesterolemia, as well as in different patient subgroups.</div></div>","PeriodicalId":53212,"journal":{"name":"Medicina de Familia-SEMERGEN","volume":"51 4","pages":"Article 102460"},"PeriodicalIF":0.9,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143680931","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Una mirada optimista hacia el presente futurista: la IA al servicio de la Atención Primaria

IF 0.9

Medicina de Familia-SEMERGEN Pub Date : 2025-03-01 DOI: 10.1016/j.semerg.2025.102450

Albert Bellvert Rios

引用次数: 0

Conjuntivitis hemorrágica aguda como manifestación ocular en un caso de infección por sarampión pese a vacunación adecuada

IF 0.9

Medicina de Familia-SEMERGEN Pub Date : 2025-03-01 DOI: 10.1016/j.semerg.2025.102472

R. García Risco, P. Buck Espel, A. Arnaiz Camacho, P. García Valentín, M.A. Zapata Victori

引用次数: 0

Mujer con hiperamilasemia, prurito y eccema generalizado

IF 0.9

Medicina de Familia-SEMERGEN Pub Date : 2025-03-01 DOI: 10.1016/j.semerg.2025.102456

S. Labrador-Descalzo , S. Cué Herreria , M. Valle-Coca

引用次数: 0